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Summary
 
Vascular permeability factor/vascular endothelial cell growth factor (VPF/VEGF) can both po-
tently enhance vascular permeability and induce proliferation of vascular endothelial cells. We
report here that mouse or human mast cells can produce and secrete VPF/VEGF. Mouse mast
cells release VPF/VEGF upon stimulation through Fc
 
e 
 
receptor I (Fc
 
e
 
RI) or c-kit, or after
challenge with the protein kinase C activator, phorbol myristate acetate, or the calcium iono-
phore, A23187; such mast cells can rapidly release VPF/VEGF, apparently from a preformed
pool, and can then sustain release by secreting newly synthesized protein. Notably, the Fc
 
e
 
RI-
dependent secretion of VPF/VEGF by either mouse or human mast cells can be significantly
increased in cells which have undergone upregulation of Fc
 
e
 
RI surface expression by a 4-d
preincubation with immunoglobulin E. These findings establish that at least one cell type, the
mast cell, can be stimulated to secrete VPF/VEGF upon immunologically specific activation
via a member of the multichain immune recognition receptor family. Our observations also
identify a new mechanism by which mast cells can contribute to enhanced vascular permeabil-
ity and/or angiogenesis, in both allergic diseases and other settings.
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M
 
ast cells are widely distributed in the connective tis-
sues of mammals and other vertebrates, where they
are frequently located in close proximity to blood vessels
(1, 2). Several lines of evidence, many of them derived
from morphological studies, have implicated mast cells in
the regulation of physiological or pathological examples of
angiogenesis, including that associated with hemangiomas
(3) and other neoplasms (4, 5), rheumatoid arthritis (6),
wound healing (7), and ovulation (8). Although the impor-
tance of mast cells as a source of proangiogenic factors in
such settings largely remains to be determined, mast cells
have been shown to secrete several mediators which might
contribute to various aspects of neovascularization, includ-
ing heparin (9, 10), TNF-
 
a 
 
(11), TGF-
 
b 
 
(12), basic fibro-
blast growth factor (13), and tryptase (14).
In this study, we evaluated whether mast cells can secrete
the multifunctional cytokine vascular permeability factor/
vascular endothelial cell growth factor (VPF/VEGF).
 
1
 
 VPF/
VEGF, which can be expressed by many types of normal or
transformed cells (15, 16), is required for embryonic and
physiological vascular development (15–17) and is thought
to contribute significantly to tumor neovascularization and
other pathological forms of angiogenesis (15, 16, 18). VPF/
VEGF can also potently increase venular permeability to
small and large molecules, both in the context of angiogen-
 
1
 
Abbreviations used in this paper:
 
 Act D, Actinomycin D; BMCMC, mouse
bone marrow–derived cultured mast cell(s); FBS, fetal bovine serum;
HSA, human serum albumin; HMC, umbilical cord blood–derived hu-
man mast cell(s); 5-HT, 5-hydroxytryptamine; ISH, in situ
 
 
 
hybridization;
PMC, peritoneal mast cell(s); rhSCF, recombinant-methionyl human
stem cell factor; rrSCF, recombinant rat stem cell factor
 
164
 
; SCF, stem cell
factor; VPF/VEGF, vascular permeability factor/vascular endothelial cell
growth factor.
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esis and in other settings (15, 19–21). Stimulation of certain
cells via cytokine receptors can enhance expression of
VPF/VEGF (15, 16). However, there has been no report
of any cell type in which VPF/VEGF secretion can be ini-
tiated upon immunologically specific activation of the cells.
In this study, we found that mouse or human mast cells can
produce and secrete VPF/VEGF, and can secrete VPF/
VEGF upon activation via the Fc
 
e
 
 receptor I (Fc
 
e
 
RI).
Moreover, we found that the IgE-dependent secretion of
VPF/VEGF can be significantly increased in mast cells that
have undergone IgE-dependent upregulation of their sur-
face expression of Fc
 
e
 
RI (22, 23).
 
Materials and Methods
 
Mast Cells.
 
Bone marrow–derived cultured mouse mast cells
(BMCMCs) were obtained by maintaining the femoral bone mar-
row cells of 4–6-wk-old BALB/c mice (Charles River Labora-
tories, Wilmington, MA) in suspension in IL-3–containing condi-
tioned complete medium, consisting of 10% heat-inactivated fetal
bovine serum (FBS; Sigma Chemical Co., St. Louis, MO), 50 
 
m
 
M
 
b
 
-mercaptoethanol (Sigma Chemical Co.), and 2 mM 
 
l
 
-glutamine
(GIBCO BRL, Gaithersburg, MD) in DMEM (GIBCO BRL)
supplemented with 20% (vol/vol) of supernatants from WEHI-3
cell–conditioned medium; the cells were resuspended in fresh con-
ditioned medium one to two times per week (24). After 4–5 wk, at
least 95% of cells that remained in the cultures were identifiable as
mast cells, as determined by toluidine blue or May-Grünwald/
Giemsa staining. Cl.MC/C57.1 mast cells, a cloned, growth fac-
tor–independent mouse mast cell line of BALB/c origin (25, 26),
were maintained as described (27). Rat peritoneal mast cells (rat
PMCs) were purified from adult (175–200 g) male Wistar rats
(Charles River Laboratories) exactly as described (28).
Mouse PMCs were purified from female retired breeder
BALB/c mice (11). In brief, groups of 60 mice were killed by
CO
 
2
 
 inhalation, the abdominal skin was washed with 70% etha-
nol, the peritoneum was exposed by a 1–2 cm midline abdominal
incision, and 5.0 ml of sterile, pyrogen-free 0.9% NaCl and 5.0
ml of air were injected into the peritoneal cavity via a 25-gauge
needle. The abdomen was massaged gently for 
 
z
 
3 min, and the
peritoneal fluid was recovered in a syringe via a 22-gauge needle,
centrifuged at 1,000 rpm (
 
z
 
209 
 
g
 
) for 10 min at room tempera-
ture, resuspended in standard medium (DMEM supplemented
with 10% heat-inactivated FBS, 2 mM 
 
l
 
-glutamine, and 50 
 
m
 
M
 
b
 
-mercaptoethanol), at which time 
 
z
 
0.9% of the 
 
z
 
2.8 
 
3
 
 10
 
8
 
peritoneal cells were mast cells according to Kimura stain. The
cells were washed once and then resuspended in 5.0 ml of stan-
dard medium, layered onto 5.0 ml of 23% metrizamide (Accurate
Chemical and Science Corp., Westbury, NY) in standard me-
dium, centrifuged at 1,500 rpm (
 
z
 
469 
 
g
 
) for 15 min at room
temperature, and resuspended in standard medium (at which time
4.2% of the cells were mast cells), then layered in 2.5 ml over 2.5
ml of 23% metrizamide in standard medium, centrifuged at 1,500
rpm (
 
z
 
469 
 
g
 
) for 15 min at room temperature, and resuspended
in standard medium, at which time mast cells represented 95–99%
of the 3.6–5.4 
 
3 
 
10
 
5
 
 cells recovered.
Umbilical cord blood–derived human mast cells (HMCs) were
generated as described elsewhere (23), in medium containing re-
combinant human stem cell factor (rhSCF, 80 ng/ml) and rhIL-6
(50 ng/ml; both from Amgen, Inc., Thousand Oaks, CA), and
1 
 
m
 
M PGE
 
2
 
 (Cayman Chemical Co., Inc., Ann Arbor, MI).
 
Activation of Mast Cells.
 
BMCMCs or Cl.MC/C57.1 cells
were incubated for 4 d either with no IgE or with 5 
 
m
 
g/ml of a
mouse IgE anti-DNP mAb (29; added as an aliquot from a stock
solution of ascites containing 1.7 mg IgE/ml). The cells were
then sedimented and resuspended at 3 
 
3 
 
10
 
6
 
 cells/ml of complete
medium (BMCMCs), or for Cl.MC/C57.1 cells, in the same me-
dium that was not supplemented with IL-3, and then passively
sensitized with 10 
 
m
 
g/ml mouse IgE anti-DNP for 50 min at
4
 
8
 
C. Sensitized cells were washed three times in DMEM contain-
ing 5% FBS and resuspended at 4 
 
3 
 
10
 
6
 
 cells/ml (for time course
experiments) or 6 
 
3 
 
10
 
6
 
 cells/ml (for dose response experiments
and experiments using inhibitors), in standard medium. Mast cell
activation was induced in multiwell plates by mixing equal vol-
umes of cell suspension and standard medium containing twice
the desired final concentration of challenging agents: DNP–
human serum albumin (DNP-HSA; Sigma Chemical Co.), the
protein kinase C activator PMA (Sigma Chemical Co.), the cal-
cium ionophore A23187 (Sigma Chemical Co.), or the c-kit
ligand, 
 
Escherichia coli
 
–derived recombinant rat stem cell factor
 
164
 
(rrSCF; Amgen, Inc. [2]). HMCs were incubated with or without
human myeloma IgE for 4 d, then passively sensitized with human
myeloma IgE and challenged with anti–human IgE exactly as
described (23). Mouse PMCs were stimulated for 2 h with PMA
(50 ng/ml in standard medium) or, as a control, with standard me-
dium (vehicle) alone.
 
RNA Isolation and Northern Blot Analysis.
 
Total cellular RNA
was isolated as described (30), and Northern blot analyses were
performed using BioTrans nylon supported membranes (ICN
Biomedicals Inc., Irvine, CA) as described by the manufacturer.
The mouse VPF/VEGF
 
164
 
 cDNA probe was the 980-bp frag-
ment described previously (30), and a G3PDH cDNA probe (24)
was used in all experiments to control for RNA loading, blotting,
and hybridization. cDNA fragments were radiolabeled with a
random-primed synthesis kit (Multi-Prime; Amersham Pharmacia
Biotech, Inc., Piscataway, NJ). Blots were washed at high strin-
gency (0.1
 
3
 
 SSC, 1% SDS, 65
 
8
 
C) and exposed on X-OMAT
film (Eastman Kodak Co., Rochester, NY).
 
Measurement of Mediators.
 
For measurements of serotonin (5-
hydroxytryptamine [5-HT]) release, BMCMCs or Cl.MC/C57.1
cells were incubated with ascites IgE at 10 
 
m
 
g/ml and [
 
3
 
H]5-HT
(New England Nuclear, Boston, MA) at 2 
 
m
 
Ci/ml for 2 h at
37
 
8
 
C, washed, and stimulated at 37
 
8
 
C for 10 min, or, as specified,
for 10, 60, or 120 min with or without inhibitors. Histamine re-
lease from HMCs was measured in supernatant and cell fractions,
in an aliquot taken 1 h after challenge, using a radioimmunoassay
kit (Immunotech, Inc., Westbrook, ME). The percentage of his-
tamine or 5-HT released was calculated according to the follow-
ing formula: % histamine or 5-HT release 
 
5 
 
[(histamine or
[
 
3
 
H]5-HT in the supernatant)/(histamine or [
 
3
 
H]5-HT in the su-
pernatant 
 
1
 
 histamine or [
 
3
 
H]5-HT in the pellet)] 
 
3 
 
100. VPF/
VEGF was measured using ELISA kits for mouse or human VPF/
VEGF (R&D Systems, Inc., Minneapolis, MN).
 
In Situ Hybridization.
 
Cytospins of freshly purified mouse
PMCs were fixed in 4% paraformaldehyde for 15 min and then
stored in 70% ethanol before processing for in situ hybridization
(ISH) with 
 
35
 
S-labeled rat VPF/VEGF antisense and sense ribo-
probes (31) exactly as described previously (32). The antisense ri-
boprobe hybridizes specifically with a region of VPF/VEGF
mRNA common to all known VPF/VEGF splicing variants (31).
The slides were examined by a single observer (L.F. Brown) who
was unaware of the identity of the individual specimens, and at
least 400 cells in each slide were scored as having 
 
$
 
10, 5–9, or
 
,
 
5 associated silver grains. One or two different slides for each 
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condition were examined in two different experiments which
gave very similar results; accordingly, the results were pooled for
statistical analysis.
 
Immunocytochemistry.
 
Cytospins of purified mouse PMCs
were fixed in 4% paraformaldehyde in PBS for 15 min and
washed three times in PBS. The cells were permeabilized with
70% ethanol at 4
 
8
 
C for 1 h and then rehydrated in PBS for 1 h.
Slides were blocked in 1% BSA in PBS for 2 h at room tempera-
ture and then incubated at 4
 
8
 
C for 18 h in 1% BSA in PBS con-
taining 
 
z
 
0.1 mg/ml of either a control purified rabbit IgG or an
affinity-purified rabbit anti–mouse NH
 
2
 
-terminal VPF/VEGF
antibody (33). The slides were washed three times for 15 min in
PBS, incubated with an FITC-goat anti–rabbit IgG conjugate
(Sigma Chemical Co.) at 1:1,000 dilution for 1 h, then washed
five times for 10 min in PBS. The slides were mounted in aque-
ous mounting medium (Gel/Mount; Biomeda, Foster City, CA)
and visualized with a confocal microscope (model MRC1024;
Bio-Rad Laboratories, Hercules, CA). Identical power and gain
levels were used to capture each image for comparison. Positive
cells were enumerated in five different fields in each specimen
(
 
n
 
 
 
5 
 
28–40 cells/field) by a single observer (K.P. Claffey) who
was unaware of the identity of the individual specimens.
 
Statistics.
 
Unless otherwise specified, all data are expressed as
mean 
 
6
 
 SEM, and all differences between values were compared
using the two-tailed Student’s 
 
t
 
 test.
 
Results and Discussion
 
Mouse Mast Cells Exhibit Increased Levels of VPF/VEGF
mRNA after Stimulation via Fc
 
e
 
RI or with PMA.
 
We used
reverse transcription PCR to search for expression of VPF/
VEGF mRNA in Cl.MC/C57.1 cloned mouse mast cells
of BALB/c origin (25, 26), mouse BMCMCs (
 
.
 
95%
pure), mouse PMCs (95–99% pure), and rat PMCs (
 
.
 
99%
pure); we used the two primer sequences reported by Cul-
linan-Bove and Koos (34) after two mismatches in the 5
 
9
 
primer had been corrected to obtain a full match to the rat
and mouse VPF/VEGF sequences (35). These primers can
amplify three forms of VPF/VEGF (VPF/VEGF
 
120
 
, VPF/
VEGF
 
164
 
, and VPF/VEGF
 
188 and/or 206
 
; references 15 and
16), and the resulting PCR products exhibited different
sizes for each of the three forms. All of the rodent mast
cell populations tested constitutively expressed mRNA for
VPF/VEGF
 
120
 
 and VPF/VEGF
 
164
 
 and, in tests of both
mouse BMCMCs and rat PMCs, the signals were en-
hanced in mRNA extracted from cells 4 h after they had
been stimulated by Fc
 
e
 
RI cross-linking (data not shown).
Using agarose gel electrophoresis and ethidium bromide
staining, we also detected, in some of these specimens, very
weak signals which probably represented expression of
VPF/VEGF
 
188 and/or 206
 
. Northern analysis of mRNA
isolated from Cl.MC/C57.1 cells using a mouse VPF/
VEGF
 
164 
 
cDNA probe (30) showed a low level of constitu-
tive expression of VPF/VEGF mRNA in unstimulated
cells and increased levels during the first 2 h after stimula-
tion (Fig. 1). However, levels of VPF/VEGF mRNA were
much higher 2 h after stimulation with PMA (50 ng/ml)
than after sensitization with IgE (10 
 
m
 
g/ml for 30 min) and
2 h of stimulation with antigen (DNP-HSA at 50 ng/ml);
in either case, mRNA levels declined markedly by 8–24 h
after stimulation (Fig. 1).
 
Mouse PMCs Express VPF/VEGF mRNA and Protein.
 
To assess whether freshly isolated mouse mast cells can ex-
press VPF/VEGF, we performed two experiments in which
PMCs were purified from groups of 60 BALB/c mice, and
then the PMCs (purities of 95 and 99%) were stimulated
with PMA (50 
 
m
 
g/ml) for 2 h at 37
 
8
 
C. In both experi-
ments, ISH analysis of cytocentrifuge preparations showed
that PMA treatment increased expression of VPF/VEGF
mRNA in mouse PMCs (compare Fig. 2 
 
A
 
, showing
PMA-treated cells hybridized to the VPF/VEGF antisense
riboprobe, with either Fig. 2 
 
B
 
, vehicle-treated cells hy-
bridized to the VPF/VEGF antisense riboprobe, or Fig. 2
 
C
 
, PMA-treated cells hybridized to the VPF/VEGF sense
probe). Silver grain count analysis confirmed that PMA
treatment enhanced VPF/VEGF mRNA expression in
mouse PMCs. Both experiments gave very similar results,
which were pooled for presentation in Fig. 2 
 
D
 
. PMA
stimulation resulted in percentages of cells that gave strongly
positive (
 
$
 
10 grains/cell) or moderately positive (5–9 grains/
cell) signals for VPF/VEGF that were threefold (6 versus 2%)
or more than threefold (18 versus 5%), respectively, those for
vehicle-treated control cells. Similar results were also ob-
tained in an analysis of mouse PMCs that had been incubated
with PMA (50 ng/ml) for 2 h after overnight culture at 37
 
8
 
C
in standard medium (data not shown).
Aliquots of the same mouse PMC preparations were an-
alyzed in cytospins by immunocytochemistry. As shown in
Fig. 3, VPF/VEGF immunoreactivity was detected in
some of the mouse PMCs that had been incubated with
medium (vehicle) alone (14.2 
 
6
 
 7.3% [mean 
 
6
 
 SD] posi-
tive cells with the anti-VPF/VEGF antibody, Fig. 3 
 
C
 
, ver-
sus 3.9 
 
6
 
 1.1% positive cells with the control antibody,
Fig. 3 
 
A
 
;
 
 P 
 
, 
 
0.035). However, enhanced VPF/VEGF im-
munoreactivity (
 
P
 
 , 
 
0.043 versus results for the vehicle-
incubated cells stained with the anti-VPF/VEGF antibody)
was observed in the cells that had been stimulated with
PMA for 2 h (26.5 
 
6
 
 8.4% positive cells with the anti-
VPF/VEGF antibody, Fig. 3 
 
D, versus 4.7 6 1.4% positive
cells with the control antibody, Fig. 3 B; P , 0.005).
Giemsa-stained cytospin preparations (Fig. 3, E and F)
show the purity of the mouse PMC populations analyzed.
Figure 1. Northern blot analysis of total RNA from C1.MC/C57.1
mast cells stimulated through FceRI (A) or with PMA (B). C1.MC/
C57.1 cells were sensitized with IgE (10 mg IgE/ml) for 30 min, washed,
and then stimulated with either 50 ng/ml DNP-HSA or 50 ng/ml PMA.
Control cells (at 0.5 and 24 h) were challenged with medium (in A) or
vehicle (0.005% DMSO, in B). Blotted total RNA from cells harvested at
various times after stimulation was probed for VPF/VEGF and G3PDH
(to demonstrate equal RNA loading).1138 Mast Cells Can Secrete VPF/VEGF
Figure 2. ISH studies of freshly isolated mouse PMCs. Expression of VPF/VEGF mRNA is higher in mast cells that had been treated with PMA (50
ng/ml) for 2 h before hybridization to an 35S-labeled antisense riboprobe (A) than in vehicle-treated (control) mast cells that had been hybridized to the
same antisense riboprobe (B). No specific signal is seen in PMA-stimulated mast cells hybridized to the 35S-labeled sense (control) riboprobe (C). Bar 5
16 mm. (D) Graphic depiction of VPF/VEGF expression by PMA- versus vehicle-treated mast cells.1139 Boesiger et al.
Mouse Mast Cells Release VPF/VEGF in Response to IgE
and Specific Antigen, PMA, A23187, or SCF, and Antigen-
dependent Release Is Markedly Enhanced after IgE-dependent Up-
regulation of Surface Expression of FceRI. Because of the large
numbers of mice required to generate highly purified prep-
arations of PMCs (60 mice yield z3–6 3 105 mast cells of
95–99% purity) and the sensitivity of the VPF/VEGF
ELISA assay, we used in vitro–derived mast cells for studies
of VPF/VEGF secretion. To examine whether mouse mast
cells can secrete VPF/VEGF protein in response to various
types of stimuli, we tested BMCMCs which either had or
had not undergone upregulation of FceRI surface expres-
sion by a 4-d preincubation with IgE at 5.0 mg/ml (22).
Mouse BMCMCs that were not preincubated for 4 d with
IgE, but were sensitized with IgE for only 2 h before anti-
gen challenge, gave z10% specific release of 5-HT (Fig. 4
B) in response to DNP-HSA and, by 6 h after stimulation
with antigen at 10 or 50 ng/ml, released a small but statisti-
cally significant amount of VPF/VEGF (z2.5 times levels
in control cells that were not stimulated with antigen; P ,
0.005, Fig. 4 A). However, in accord with our previous
findings (22), preincubation of BMCMCs with 5 mg IgE/
ml for 4 d before further sensitization and antigen stimula-
tion resulted in an approximately twofold increase in spe-
cific release of 5-HT compared with cells not preincubated
with IgE for 4 d (Fig. 4 B). The enhancement of VPF/
VEGF secretion was even more striking (at 100 ng anti-
gen/ml, to approximately nine times the levels produced
by cells that had not been preincubated with IgE for 4 d;
Fig. 4 A).
The markedly enhanced IgE-dependent release of VPF/
VEGF from BMCMCs after a 4-d preincubation with IgE
is in accord with our finding that such BMCMCs also ex-
hibited greatly enhanced IgE- and antigen-dependent se-
cretion of IL-4 and IL-6 (22). However, stimuli other than
IgE and antigen gave very different patterns of 5-HT and
Figure 3. Immunofluorescent
detection of VPF/VEGF immu-
noreactivity in a highly purified
(99% pure) population of freshly
isolated mouse PMCs. (A and B)
Little or no staining of PMCs
that had been incubated for 2 h
with vehicle alone (A) or PMA
(50 ng/ml; B) before incubation
with a control rabbit IgG prepa-
ration (IgG). (C and D) VPF/
VEGF immunoreactivity was
detected with a rabbit anti-VPF/
VEGF (a-VEGF) antibody in
some PMCs that had been incu-
bated for 2 h with either vehicle
alone (C) or PMA (50 ng/ml;
D). Black bar in A (for A–D) 5
50  mm. (E and F) Giemsa-
stained cytospin preparations of
the same vehicle- (E) or PMA-
(F) stimulated purified PMCs
that were used for immunofluo-
rescent detection of immunore-
activity (A–D). Black bar in E
(for  E and F) 5 50 mm.1140 Mast Cells Can Secrete VPF/VEGF
VPF/VEGF release by BMCMCs, and these responses
were not substantially affected by preincubation of the cells
in IgE for 4 d. PMA induced levels of VPF/VEGF secre-
tion that were approximately four times those of the high-
est levels of FceRI-dependent release (Fig. 4 A), but this
was associated with minimal release of 5-HT (Fig. 4 B).
The calcium ionophore A23187 induced release of both
5-HT and VPF/VEGF, whereas the c-kit ligand SCF in-
duced little or no VPF/VEGF release in 6 h, and a minimal
amount of 5-HT release (Fig. 4, A and B).
The kinetics of VPF/VEGF release from BMCMCs that
were stimulated with fixed concentrations of DNP-HSA
(50 ng/ml), PMA (50 ng/ml), A23187 (1 mM), or SCF
(500 ng/ml) are shown in Fig. 5. We controlled the exper-
imental conditions to exclude hypoxia (which can enhance
VPF/VEGF production in other cell types [36]) by using a
maximum final concentration of 2 3 106 cells/ml, by stim-
ulating the cells in multiwell plates filled to ,40%, and by
mixing the cell suspension carefully every 2 h.
Unstimulated BMCMCs constitutively released a small
amount of VPF/VEGF, a process that was unaffected by a
4-d pretreatment with IgE. This constitutive release rate, as
determined by linear regression analysis, was 0.18 6 0.08
pg/106 cells ? h21 (mean 6 SD; n 5 10). Cells that had not
been preincubated with IgE for 4 d released z2.3 pg VPF/
VEGF/106 cells in response to 50 ng/ml of DNP-HSA,
primarily within the first 3 h after stimulation, whereas
BMCMCs that had been pretreated with IgE at 5 mg/ml
for 4 d released much larger amounts of VPF/VEGF, and
release persisted for at least 24 h. Release of VPF/VEGF in
response to A23187 also reached near maximal levels at
3 h. PMA stimulation resulted in the rapid induction of
VPF/VEGF, which reached a plateau after z12 h, perhaps
reflecting PMA-induced degradation of certain protein ki-
nase C isoforms (37).
rrSCF (at 500 ng/ml) significantly enhanced release of
VPF/VEGF only when the BMCMCs were exposed to
this growth factor for .12 h (Fig. 5). By contrast, we re-
ported recently that rrSCF can induce such BMCMCs to
release IL-6 within 30 min of stimulation (27). Because
IL-6 can induce VPF/VEGF expression in several cell lines
(38), we tested whether IL-6 can stimulate BMCMCs to
Figure 4. Release of (A) VPF/VEGF (in 6 h) and (B) serotonin (5-HT, in 10 min) from BMCMCs that exhibit different levels of surface expression of
FceRI, after challenge with various concentrations of either specific antigen (DNP-HSA), the protein kinase C activator PMA, the calcium ionophore
A23187, or SCF. BALB/c BMCMCs were cultured without IgE or with IgE at 5.0 mg/ml for 4 d before passive sensitization and antigen challenge or
challenge with A23187, PMA, or SCF for 6 h. 0 in the PMA and A23187 experiments refers to cells incubated without PMA or A23187, respectively,
but in the highest concentration of vehicle used for these studies (DMSO at 0.5%). All values are mean 6 SEM (n 5 8/point) of data pooled from two
experiments with different batches of BMCMCs (each n 5 4/point) that gave very similar results. *P , 0.05, **P , 0.005, or ***P , 0.0001 versus
corresponding control values for unstimulated or vehicle-treated cells. †P , 0.05, ††P , 0.005, or †††P , 0.0001 versus corresponding values for cells cul-
tured without IgE for 4 d. Note the different VPF/VEGF scale for PMA stimulation.1141 Boesiger et al.
release VPF/VEGF. BMCMCs preincubated with either
no IgE or 5 mg IgE/ml for 4 d were stimulated with re-
combinant mouse IL-6 (R&D Systems, Inc.) in concentra-
tions between 10 and 500 ng/ml for 12 h, but no release of
VPF/VEGF above control levels could be detected (data
not shown). Similarly, exposure of BMCMCs to active re-
combinant TGF-b1 (2 or 10 ng/ml; R&D Systems, Inc.),
another potentially mast cell–derived cytokine (12) that can
stimulate VPF/VEGF production in certain cell types (39),
for 12 h did not induce detectable release of VPF/VEGF
(data not shown).
FceRI-dependent Stimulation of BMCMCs or Cl.MC/
C57.1 Mast Cells Induces the Release of Both Preformed and
Transcriptionally Induced VPF/VEGF. We found that the
majority of VPF/VEGF released in response to stimulation
with A23187, or with IgE and antigen in BMCMCs that
had not been pretreated with IgE for 4 d, occurred within
the first 3 h after stimulation (Fig. 5). Therefore, we as-
sessed whether a fraction of the VPF/VEGF secreted by
these cells, like mast cell–derived TNF-a (11), might be re-
leased from a preformed pool. Cl.MC/C57.1 cells and
BMCMCs were sensitized for 2 h with 10 mg/ml of mouse
IgE, washed, then preincubated with or without the inhib-
itor of intracellular protein transport, Brefeldin A (5 mg/ml;
Sigma Chemical Co. [40]), or the transcription inhibitor
Actinomycin D (Act D, at 10 mg/ml; Sigma Chemical Co.
[11]) for 5 min. Cells were then challenged for 10, 60, or
120 min (with our without the inhibitor) with 50 ng/ml
DNP-HSA or with medium alone (Fig. 6). Neither inhibi-
tor induced a significant reduction in cell viability during
the experiments, as assessed by trypan blue exclusion (22).
Stimulation with specific antigen rapidly induced de-
granulation of BMCMCs, as reflected in increased levels of
5-HT in the cells’ supernatant and a parallel reduction in
the cell-associated content of 5-HT, at 10 or 60 min after
stimulation, to levels z33 or 44% lower than those in the
unstimulated cells at baseline (Fig. 6 A). And, in accord
with previous findings with rat basophilic leukemia cells
(37) or BMCMCs (11), neither Brefeldin A nor Act D had
a substantial effect on 5-HT release (Fig. 6 A).
The VPF/VEGF content of these cells also dropped sig-
nificantly by 10 or 60 min after antigen challenge (by z25
or 36% versus initial values for unstimulated cells), with a
corresponding significant increase in the levels of VPF/
VEGF in the cells’ supernatant (Fig. 6 B). The changes at
10 min were only minimally affected by Brefeldin A,
whereas Act D had little or no effect on FceRI-dependent
secretion of VPF/VEGF at either 10 or 60 min (Fig. 6 B).
By contrast, either Brefeldin A or Act D significantly re-
duced the levels of VPF/VEGF secreted by 2 h after stimu-
lation, to levels which approximated those released in the
first 10 min after activation (Fig. 6 B). Brefeldin A treat-
ment also significantly enhanced levels of cell-associated
VPF/VEGF in IgE- and antigen-activated BMCMCs by
2 h after stimulation, whereas Act D treatment had the op-
posite effect (Fig. 6 B).
The simplest explanation for these findings is that the
VPF/VEGF secreted by BMCMCs at early intervals after
FceRI cross-linking includes a fraction that is derived from
preformed stores. However, in accord with the findings
shown in Fig. 1, the data in Fig. 6 also indicate that the
VPF/VEGF released from the cells at later intervals after
FceRI-dependent stimulation reflects the de novo synthesis
of VPF/VEGF through gene transcription, and the release
of the protein by a Brefeldin A–sensitive mechanism.
An identically designed experiment with Cl.MC/C57.1
cells gave results that were qualitatively similar to those ob-
tained in our two experiments with BMCMCs (data not
Figure 5. Kinetics of the release of VPF/VEGF from BALB/c BMCMCs that exhibit different levels of surface expression of FceRI, after challenge
with either specific antigen (DNP-HSA, at 50 ng/ml), PMA (50 ng/ml), A23187 (1 mM), or SCF (500 ng/ml). BMCMCs were cultured without IgE or
with IgE at 5.0 mg/ml for 4 d before passive sensitization and antigen challenge or challenge with A23187, PMA, or SCF. Cells used as unstimulated con-
trols for DNP-HSA– or SCF-stimulated cells were maintained in medium alone. PMA- or A23187-stimulated cells were compared with cells maintained
in medium containing vehicle (DMSO at 0.1%). All values are mean 6 SEM (n 5 8/point) of data pooled from two experiments with different batches
of BMCMCs (each n 5 4/point) that gave very similar results. *P , 0.05, **P , 0.005, or ***P , 0.0001 versus corresponding control values for un-
stimulated or vehicle-treated cells. †P , 0.05, ††P , 0.005, or †††P , 0.0001 versus corresponding values for cells cultured without IgE for 4 d. Note the
different VPF/VEGF scale for PMA.1142 Mast Cells Can Secrete VPF/VEGF
shown). However, Cl.MC/C57.1 mast cells, which are tu-
morigenic in vivo (26), constitutively released VPF/VEGF
at a much higher rate than did BMCMCs. By linear regres-
sion analysis, the rate of constitutive release of VPF/VEGF
by Cl.MC/C57.1 cells was 3.43 6 0.49 pg/106 cells ? h21
(mean 6 SD; n 5 3), z19-fold that for BMCMCs. This
constitutive secretion of VPF/VEGF, but not the cells’
constitutive release of 5-HT, was significantly reduced by
Brefeldin A (z66% reduction at 2 h, P , 0.005 versus val-
ues for control cells without Brefeldin A). These findings
support the conclusion that VPF/VEGF can be constitu-
tively translocated by mast cells to the extracellular space,
apparently without the involvement of the cytoplasmic
granules.
HMCs Produce and Secrete VPF/VEGF.  We showed re-
cently that incubation with human myeloma IgE can up-
regulate HMC FceRI expression and that this results in
enhanced anti-IgE–dependent mast cell release of histamine
and macrophage inflammatory protein 1a (23). HMCs
were incubated with either no IgE or with 5 mg/ml of hu-
man myeloma IgE for 4 d before further passive sensitiza-
tion with IgE and challenge with goat anti–human IgE an-
tibody for up to 16 h. Fig. 7 shows the results from one of
three similar experiments. We found that HMCs (which,
to maintain their viability, must be maintained continu-
ously in rhSCF-containing medium) secrete VPF/VEGF in
the absence of FceRI-dependent activation. However, sig-
nificantly increased amounts of VPF/VEGF (Fig. 7 A) and
histamine (Fig. 7 B) were released after cell stimulation
through FceRI cross-linking. Pretreatment of HMCs with
IgE for 4 d significantly enhanced both spontaneous (by
z20%) and anti-IgE–induced (by z57%) release of VPF/
VEGF (Fig. 7 A), as well as anti-IgE–induced release of
histamine (Fig. 7 B), compared with results for cells with
no 4-d pretreatment with IgE. In a second experiment
with a different batch of HMCs (98% purity), IgE pretreat-
ment enhanced spontaneous release of VPF/VEGF by 38%
and the anti-IgE–induced release by 51% at 4 h. In both of
these experiments, as well as in a third experiment with
.99% pure HMCs, release of VPF/VEGF was significantly
enhanced in anti-IgE–treated as opposed to unstimulated
cells (by 42, 6, and 124% for HMCs without a 4-d prein-
Figure 6. Kinetics of release of
5-HT (A) and VPF/VEGF (B)
from BMCMCs stimulated
through the FceRI. Mast cells
were sensitized with IgE (10 mg
IgE/ml) for 2 h and then prein-
cubated as indicated for 5 min at
378C with either no inhibitor,
the inhibitor of intracellular pro-
tein transport Brefeldin A (5 mg/
ml), or the transcription inhibi-
tor Act D (10 mg/ml). Cells
were then challenged for various
time periods with DNP-HSA
(Antigen) or medium (Control).
Data for VPF/VEGF are mean 6
SEM (n 5 3/point); data for
[3H]5-HT are mean 6 SEM (n 5
4/point). *P , 0.05, †P , 0.005,
‡P , 0.0001 versus values for the
same time point in cells incu-
bated without the inhibitor, or,
as indicated (brackets), versus cor-
responding values for control
cells that were not challenged
with DNP-HSA. A second iden-
tical experiment with BMC-
MCs gave very similar results.
Figure 7.  IgE-induced enhancement of FceRI expression in human
mast cells increases the ability of these cells to release VPF/VEGF (over a
16-h period; A) and histamine (over a 1-h period; B) in response to
FceRI cross-linking. HMCs (12 wk of culture, 85% mast cell purity) were
cultured without or with human myeloma IgE at 5 mg/ml for 4 d before
further passive sensitization with IgE and challenge with goat anti–human
IgE antibody. The data shown (mean 6 SEM; n 5 3/bar) are representa-
tive of the results obtained in three separate experiments using mast cells
derived from three different cord blood donors.1143 Boesiger et al.
cubation with IgE, and by 85, 16, and 171%, respectively,
with a 4-d preincubation with IgE).
These experiments reveal three similarities in the secre-
tion of VPF/VEGF by HMCs and BMCMCs: (a) the cells
release some VPF/VEGF constitutively, under usual condi-
tions of cell culture; (b) the cells exhibit enhanced release
of VPF/VEGF in response to immunologic stimulation
through the FceRI; and (c) IgE-induced enhancement of
FceRI expression can enhance the cells’ ability to release
VPF/VEGF in response to FceRI-dependent stimulation.
Conclusions. VPF/VEGF is appropriately regarded as an
important regulator of neovascularization (15–17); how-
ever, it is also one of the most potent vascular permeability
factors yet described, with a molar potency in guinea pig
skin that is 50,000-fold that of histamine (20). Accordingly,
the finding that mast cells can produce and secrete VPF/
VEGF identifies a new mechanism by which mast cells
might regulate angiogenesis, vascular permeability, and/or
other VPF/VEGF-mediated effects on microvessels (21).
Moreover, our finding that the stimulation of mast cells
via the FceRI can enhance the cells’ ability to produce and
secrete VPF/VEGF demonstrates that VPF/VEGF can be
expressed in an immunologically specific, FcR-dependent
manner, at least by this type of effector cell. To our knowl-
edge, this also represents the first example of a cell which
can secrete VPF/VEGF upon stimulation via any member
of the multichain immune recognition family of cell surface
receptors. In addition, the observation that the ability of
mast cells to release VPF/VEGF in response to FceRI-
dependent activation is significantly enhanced in cells that
have been exposed to high concentrations of IgE indicates
that VPF/VEGF may be a particularly important mast cell–
derived mediator of augmented vascular permeability at
sites of acute or chronic allergic inflammation, or parasite
infection, in subjects with high circulating levels of IgE (22,
23, 41).
Our data indicate that the release of VPF/VEGF by mast
cells can be regulated differentially from that of preformed
mediators such as 5-HT or histamine. As with TNF-a (11),
some of the VPF/VEGF produced by mast cells can be rap-
idly secreted from an apparently preformed pool, and both
VPF/VEGF and biogenic amines were secreted upon acti-
vation of mast cell degranulation via the FceRI or by the
calcium ionophore, A23187. However, PMA induced an
even more substantial release of VPF/VEGF than did IgE
and antigen or A23187, and such PMA-induced VPF/
VEGF production was associated with minimal degranula-
tion and release of 5-HT. The latter finding indicates that it
may be of interest to search for endogenous activators of
mast cell protein kinase C that can induce the release of
VPF/VEGF preferentially over biogenic amines and other
cytoplasmic granule–associated preformed mediators.
While this manuscript was under revision, Grützkau et
al. (42) reported that the HMC-1 human mast cell leuke-
mia cell line can constitutively express and secrete three
isoforms of VPF/VEGF (of 121, 165, and 189 amino acids)
and that stimulation of the cells for 24 h with PMA (25 ng/
ml) and A23187 (250 nM) resulted in enhanced secretion
of these three VPF/VEGF isoforms and induced the ex-
pression of VPF/VEGF206. We have also observed that
HMC-1 cells can express and constitutively secrete VPF/
VEGF and can release substantially increased (z2.5-fold)
amounts of VPF/VEGF upon stimulation with PMA and
the calcium ionophore, A23187 (data not shown). In the
experiments by Grützkau et al. (42), PMA- and A23187-
stimulated HMC-1 cells released z800 pg of VPF/VEGF
per 106 cells over a 12-h period, an amount that is much
higher (by approximately ninefold) than that produced by
anti-IgE–stimulated nonneoplastic human mast cells over a
period of 16 h (see Fig. 7). These findings are in accord
with our results with the tumorigenic Cl.MC/C57.1 mouse
mast cell line of BALB/c origin, which constitutively
released VPF/VEGF at a rate that was z19-fold that of
nonneoplastic BALB/c mouse BMCMCs. Taken together,
these observations indicate that the amounts of VPF/VEGF
that can be secreted by neoplastic mast cell lines can greatly
exceed those produced by the corresponding nonneoplastic
cells. Whether this property of neoplastic mast cells can also
be expressed in vivo, for example, in those patients who
develop vascular abnormalities in association with masto-
cytosis (e.g., telangiectasia macularis eruptiva perstans [43]),
remains to be determined.
Clearly, further work will also be required to assess the
importance of nonneoplastic mast cells as a source of VPF/
VEGF in vivo. We have found that freshly isolated mouse
PMCs can exhibit enhanced expression of VPF/VEGF
mRNA and protein (as detected by ISH and immunocy-
tochemistry, respectively) after stimulation with PMA for
2 h in vitro, and Grützkau et al. (42) have detected VPF/
VEGF immunoreactivity by postembedding immunoelec-
tron microscopy in some, but not all, of the cytoplasmic
granules of partially purified human skin mast cells. These
findings indicate that in vivo–derived, as well as in vitro–
derived, nonneoplastic mast cells can express VPF/VEGF.
Moreover, Grützkau et al. (42) found that other dermal
cells in their preparations, including macrophages, vascular
endothelial cells, and fibroblasts, were negative for VPF/
VEGF protein by immunoelectron microscopy, even
though each of these cells can produce VPF/VEGF under
some circumstances in vitro (15, 16). Thus, the observa-
tions of Grützkau et al. (42) are consistent with our data in
indicating that, upon appropriate stimulation, mast cells
may be able to release some VPF/VEGF from preformed
stores. However, it remains to be determined under what
circumstances mast cells represent a critical source of VPF/
VEGF in vivo, and, in such instances, what signals regulate
the mast cell’s production and secretion of the various iso-
forms of this mediator.1144 Mast Cells Can Secrete VPF/VEGF
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